Register Now
Why register?
 The leading web portal for pharmacy resources, news, education and careers August 20, 2014
Pharmacy Choice - News - Pharmaceutical Industry Trends and Policy - August 20, 2014

Pharmacy News

 Pharmaceutical Industry Trends and Policy
Current Articles | 7 - 30 Days Old | 30 - 90 Days Old | Over 90 Days
Articles(s): 1 - 25 of 250     Next >>     Go To Page:

8/20/14 - CEL-SCI Expands its Global Phase III Cancer Trial in Canada; Oncothyreon Plunges On Drug Fail
Below is a look at some of the headlines for companies that made news in the healthcare sector on August 19 2014.{ nfg} CEL-SCI Corporation announced its Phase III Head and Neck Cancer clinical trial of its investigational cancer immunotherapy treatment Multikine* has added Centre Hospitalier Universitaire de Qubec s L Hotel Dieu de Quebec
8/19/14 - Achillion Granted U.S. Patent for ACH-3102 and Structurally Related NS5A Inhibitors
Achillion Pharmaceuticals, Inc. today announced that the U.S. Patent& Trademark Office has granted Achillion U.S. With the issuance of this patent for our differentiated NS5A inhibitor, ACH-3102, along with the previously granted patent for sovaprevir, our NS3/4A protease inhibitor, we are pleased to recognize the talented Achillion team that dis
8/19/14 - Alcobra Announces Enrollment of First Patient in Phase IIb Clinical Trial of MDX in Fragile X Syndrome
Alcobra Ltd., an emerging pharmaceutical company primarily focused on the development and commercialization of its proprietary drug candidate Metadoxine Extended Release, to treat cognitive dysfunctions, such as ADHD and Fragile X Syndrome, announced today that the first patient has been enrolled in a Phase IIb Fragile X study of MDX.
8/19/14 - Amazing Charts Engages Bio/Pharma With Appointment of Duke Reilly
Amazing Charts, a 2014 Certified Electronic Health Record system for outpatient practices, has named Duke Reilly as director of Industry Business Development. Pri-Med, our parent company, already knows many of the brand teams in the therapeutic areas of vaccines and cardio metabolic, providing Duke with a strong head start on those initiatives. "
8/19/14 - Anavex Reports That Antidepressant Fluvoxamine Reduces Stress Through Sigma-1 Receptor
Anavex Life Sciences Corp., a clinical-stage biopharmaceutical company developing novel drug candidates to treat Alzheimer's disease, other diseases of the central nervous system and various types of cancer, announced today new data published in the current issue of Cell Death and Disease that the commonly used selective serotonin reuptake inhibi
8/19/14 - AstraZeneca says DOJ closes probe into drug trial
WASHINGTON British drugmaker AstraZeneca says the U.S. Department of Justice has closed its investigation into a clinical trial of the company's blood thinner Brilinta, and plans no further action. The London- based drugmaker said in a statement Tuesday: " AstraZeneca has always had absolute confidence in the integrity of the PLATO trial."
8/19/14 - AstraZeneca says Justice probe is over [The Philadelphia Inquirer :: ]
AstraZeneca chief executive officer Pascal Soriot used the revenue possibilities to argue for declining three takeover offers from Pfizer Inc.. "As one of AstraZeneca's growth platforms, we remain committed to delivering the full potential of this important medicine," Soriot said in a statement Tuesday. Like some other big pharmaceutical companies
8/19/14 - Bioniche Announces Q1/2015 Timeline for the Filing of a Biologics License Application for Marketing Approval of MCNA in the United States
-Bioniche Life Sciences Inc. today announced that it is targeting Q1/2015 for the filing of a Biologics License Application with the United States Food and Drug Administration for Bioniche's lead program Mycobacterial Cell Wall-Nucleic Acid Complex for the treatment of patients with high grade non-muscle invasive bladder cancer that have failed...
8/19/14 - BioPharma Services Names Recipient of Lorelei Lutter Fine Arts Scholarship [Professional Services Close - Up]
According to a company release, the first scholarship will be awarded on August 8th, to Daria Savic, daughter of Natasa Bacevic- Savic, a Biopharma employee. "I am very pleased to award Daria Savic with the Lorelei Lutter Fine Arts Scholarship. BioPharma Services is a physician-owned, physician-run, FDA- inspected, UK MHRA-inspected, and Health Ca
8/19/14 - Biotech/Biosimilar Products: Current and Emerging Analytical CMC Expectations: 2-Day In-Person Seminar - San Jose, California - 6th-7th November 2014
Dublin- Research and Markets has announced the addition of the "Biotech/Biosimilar Products: Current and Emerging Analytical CMC Expectations: 2- Day In-Person Seminar" conference to their offering. In the development and commercialization of biopharmaceutical products, historically most of the R&D and GMP attention has been focused on the...
8/19/14 - Boehringer Ingelheim Announces U.S. Filing for the Fixed-Dose Combination Tiotropium Plus Olodaterol for Patients with COPD
Boehringer Ingelheim today announced that the U.S. Food and Drug Administration accepted for review the New Drug Application for the fixed-dose combination of tiotropium and olodaterol delivered via the Respimat inhaler for the proposed indication of long-term, once-daily maintenance treatment of airflow obstruction in patients with chronic...
8/19/14 - Boehringer Ingelheim Pharmaceuticals Gets FDA's Support for Tiotropium Respimat for the Maintenance Treatment of COPD [Professional Services Close - Up]
Boehringer Ingelheim Pharmaceuticals confirmed that the U.S. Food and Drug Administration Pulmonary-Allergy Drugs Advisory Committee voted that existing data supports approval of Boehringer Ingelheim's investigational tiotropium bromide inhalation spray for long-term, once-daily maintenance treatment of bronchospasm associated with...
8/19/14 - Celator(R) Pharmaceuticals Initiates Pharmacokinetic and Pharmacodynamics Clinical Study of CPX-351
Celator Pharmaceuticals, Inc., a pharmaceutical company developing new and more effective therapies to treat cancer, today announced that the first patient has been enrolled in a Phase 2 pharmacokinetic and pharmacodynamics study evaluating the effects of CPX-351 Liposome Injection on cardiac repolarization in adult patients with acute hematologi
8/19/14 - Cellceutix Completes Enrollment in Phase 2b Clinical Trial of Brilacidin for Acute Bacterial Skin and Skin Structure Infections (ABSSSI)
Cellceutix Corporation, a clinical stage biopharmaceutical company developing innovative therapies in oncology, dermatology, and antibiotic applications, has announced the completion of enrollment in its Phase 2 b trial comparing Brilacidin? to daptomycin in patients with acute bacterial skin and skin structure infections. Overall, 215 patients w
8/19/14 - Chinese firm rings NASDAQ bell [China Daily: Hong Kong Edition]
China- based and NASDAQ-listed biotech company Cellular Biomedicine Group rang the closing bell at the midtown stock exchange on Monday, having just gone public at the market two months earlier. William Cao, CEO of Cellular Biomedicine Group, and CFO Tony Liu ring the closing bell at the NASDAQ on Aug 18 in New York. Cellular Biomedicine Group is a
8/19/14 - Clinical research company looking for test subjects [Hendricks County Flyer, Avon, Ind. :: ]
Aug. 19 Community Medical Research Partners are looking for volunteers to help with pharmaceutical research. "All drugs that meet FDA approval have to go through a clinical trial process," explains Michele Hall, director of operations for CMRP. "They first start with animals and then move their way to human subjects.
8/19/14 - Clinical Studies of Safety and Effectiveness of Orphan Products Research Project Grant (R01)
SUMMARY: The Food and Drug Administration is announcing the availability of grant funds for the support of FDA's Office of Orphan Products Development grant program. The goal of FDA's Orphan Products Development grant program is to support the clinical development of products for use in rare diseases or conditions where no current therapy exists or
8/19/14 - DelMar Pharmaceuticals Provides Update on Glioblastoma Clinical Trial and Results of Warrant Tender Offer
VANCOUVER, British Columbia and MENLO PARK, Calif., Aug. 19, 2014/ PRNewswire/ DelMar Pharmaceuticals, Inc. announced today a protocol amendment to allow for expanded dosing in its VAL-083 clinical trial had been filed with the U.S. Food and Drug Administration and that a new cohort of a new 50 mg/m 2 has been opened at three clinical trial sites
8/19/14 - Depomed Prevails in Gralise ANDA Litigation Blocking Generic Entry Until 2024
Depomed, Inc. today announced Judge Joel A. Pisano of the U.S. District Court for the District of New Jersey has ruled in favor of Depomed in the company's patent litigation lawsuit against Actavis, Inc. related to Actavis's Abbreviated New Drug Application for generic versions of Depomed's Gralise tablets for the management of postherpetic ne
8/19/14 - DGAP-News: Evotec and Medicines For Malaria Venture announce a long-term compound management collaboration
DGAP-News: Evotec AG/ Key word: Alliance Evotec and Medicines For Malaria Venture announce a long-term compound management collaboration 19.08. 2014/ 07:29- Hamburg, Germany, and Branford, CT- 19 August 2014: Evotec AG today announced the start of a multi-year compound management a
8/19/14 - DGAP-News: Evotec and Medicines For Malaria Venture announce a long-term compound management collaboration (english)
Evotec and Medicines For Malaria Venture announce a long-term compound management collaboration DGAP-News: Evotec AG/ Key word: Alliance Evotec and Medicines For Malaria Venture announce a long-term compound management collaboration 19.08. 2014/ 07:29- Hamburg, Germany, and Branfor
8/19/14 - Edison Partners Announces Investment in Clinverse, Inc.
Edison Partners proudly announced today leading a $9 million growth financing of Clinverse, Inc. Based in Durham, NC, Clinverse is an emerging leader in clinical trial finance, automating millions of dollars in financial transactions for clinical trials across the globe. Co-investors include Hatteras Venture Partners. "Edison Partners is a believe
8/19/14 - Elbit Imaging: Gamida Cell Signs Deal With Novartis On Development Of NiCord
BASEL- Israel- based Elbit Imaging Ltd. noted Tuesday of its unit Elbit Medical Technologies Ltd.' s announcement that Gamida Cell Ltd., in which Elbit Medical holds approximately 30.8 percent of the voting power, as well as Gamida Cell's majority shareholders, signed Option and Investment agreements with Novartis Pharma AG, a unit of Swiss pharmac
8/19/14 - Eli Lilly: FDA Grants Tentative Approval For Insulin Drug Basaglar
INDIANAPOLIS- Eli Lilly and Co said Monday the U.S. Food and Drug Administration granted tentative approval for Basaglar, which is indicated to improve glycemic control in adults with type 2 diabetes and in combination with mealtime insulin in adults and pediatric patients with type 1 diabetes. Basaglar is Eli Lilly and Boehringer Ingelheim's basal
8/19/14 - EnGeneIC Secures Patent for EDV Nanocell Technology [Professional Services Close - Up]
EnGeneIC reported that the United States Patent and Trademark Office issued U.S. Patent No. 8,772,013 to EnGeneIC for its patent application entitled, "Methods for Targeted in Vitro and in Vivo Drug Delivery to Mammalian Cells via Bacterially Derived Intact Minicells." Jennifer MacDiarmid, Ph.D., joint-CEO of EnGeneIC, said, "This patent marks a su
Articles(s): 1 - 25 of 250     Next >>     Go To Page:

© 2014 Thomson Reuters. All rights reserved.

Pharmacy News Index
  Drug Delivery Systems
  FDA Final Approvals
  Front Page Healthcare News
  Generic Drugs
  Hospital Industry
  Internet Pharmacy
  IT in Healthcare
  Medicare & Medicaid
  Over-the-Counter Drugs
  Pharm Industry Trends and Policy
  Pharmaceutical Development
  Pharmaceutical Industry


Lupus: What You Need to Know
This lesson is supported by:
West Virginia Best Practice Prescribing & Drug Diversion Training
This lesson is supported by:

Special Announcement

Free Membership
Enjoy Drug Search, industry newsletters and more...

Websites »
Copyright © 2009 Pharmacy Choice - All rights reserved.
Terms and Conditions | Privacy Statement